The Molecular Diagnostics Section is currently the only CLIA and College of American Pathology approved clinical laboratory within the NCI certified for performing molecular oncology testing on pathology materials from NIH patients. The newly established COMPASS program is to expand next-generation sequencing to support clinical and research in CCR. In FY24 (July 2023 - June 2024), the NGS lab run 1495 TSO500, whole exome sequencing, and RNA exome sequencing tests. It was 14.2% less than the same period last year. This decrease mostly was reflexed from reducing NGS testing for non-CCR principal investigators. These results have provided support of precision pathological diagnosis and precision oncology for 80 clinical protocols from NCI and 15 protocol from NHGRI, NIAID, NIAMS, NIDDK including CCR Rare Tumor, Liver and Prostate Cancer Moonshot projects (starting October 1st, 2023, all non-NCI protocols have stopped ordering COMPASS NGS testing due to the reagent charges by CCR). We are also screening the targets in patients from CCR intramural clinics for NCI-MATCH. As a part of CCR precision medicine development, in FY24, we used additional funds from the clinical NGS testing to continue evaluation, testing, and development of cell-free DNA extraction and cell-free circulating tumor DNA (ctDNA) NGS assay web-beach process and sequencing. ctDNA NGS is almost ready to move onto pre-clinical validation phase for FY25. If FY25 budge allows, the ctDNA test could be offered to test real-time patient specimens. The COMPASS program provided the great opportunities of training or continuing education for both pathology and oncology teams especially next generation of pathologists and physician scientists by running weekly NGS technical review conference, weekly molecular pathology/neuro-oncology conference, and weekly molecular pathology/pediatric oncology conference to discuss molecular finding, treatment, and beyond particular patient or mutation.